Decoy Therapeutics Inc.
Income Statement
| Line Item | Aug 2026 | Jun 2026 | May 2026 | Mar 2026 | Mar 2026 | Dec 2025 | Nov 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $227.6K | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $1.3M | — | $749.8K | — | — | — | $61.8K |
| SG&A Expense | — | $1.3M | — | $1.5M | — | — | — | $833.3K |
| Operating Income | — | $-2.6M | — | $-2.3M | — | — | — | $-895.1K |
| Operating Margin | — | -1,155.8% | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | — | $-2.4M | — | $-2.2M | — | — | — | $-873.5K |
| Net Margin | — | -1,042.8% | — | — | — | — | — | — |
| EPS (Basic) | — | $-4.46 | — | $-4.18 | — | — | — | $-1.81 |
| EPS (Diluted) | — | $-4.46 | — | $-4.18 | — | — | — | $-1.81 |
| Shares Outstanding (Basic) | 655.2K | 532.0K | 532.0K | 532.0K | 532.0K | 532.0K | 5.9M | 481.6K |
| Shares Outstanding (Diluted) | 655.2K | 532.0K | 532.0K | 532.0K | 532.0K | 532.0K | 5.9M | 481.6K |
| Dividends Per Share | — | — | — | — | — | — | — | — |